TwinCaps® in Phase III clinical trials for influenza
Hovione’s TwinCaps® inhaler in Phase III clinical trials for influenza
Oops! Your browser version is not supported by our website.
Please use these following browsers to view this page:
Hovione’s TwinCaps® inhaler in Phase III clinical trials for influenza
Hovione advanced characterization capabilities of inhalation and nasal products is crucial to determine their safety and efficacy.
Hovione, the specialist integrated CDMO, just announced an expansion of its nasal drug delivery capabilities with the addition of a family of innovative nasal powder delivery devices developed in partnership with IDC.
Drug Delivery Technology, April 2010
ONdrugDelivery, 2014, December, pp. 16 - 23
Fully-integrated Filling for your device needs.
Spray drying has become one of the most successful particle engineering technologies for improving drug bioavailability through the amorphous solid dispersion platform.
European Industrial Pharmacy, June 2013